Abstract

Desloratadine is a second-generation nonsedating antihistamine currently used in the treatment of allergic rhinitis and chronic idiopathic urticaria. It is the major active metabolite of loratadine. The binding affinity of desloratadine for H1 receptors is the highest among all antihistamines. Besides the effects of desloratadine on H1 receptors, it may also reduce the release of anti-inflammatory cytokines and other mediators involved in the early- and late-phase allergic response. Desloratadine is well-tolerated, and most adverse events reported are mild/moderate and experienced by a small proportion of the patients. Many large, randomized, double-blind, placebo-controlled trials have confirmed that desloratadine is effective against symptoms of intermittent and persistent allergic rhinitis. Patients with chronic idiopathic urticaria also experience marked relief of symptoms upon treatment with desloratadine, since urticarial symptoms in chronic idiopathic urticaria are largely mediated by histamine.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.